InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,481.11
(
0.14%
)
US TECH 100
19,386.40
(
-0.08%
)
Dow Jones
38,777.87
(
0.00%
)
Brent Oil
84.40
(
0.59%
)
Bitcoin
65,320.38
(
-1.75%
)
Post# of 252235
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

steveporsche

Send PM Follow Ignore
Followers 2
Posts 283
Boards Moderated 0
Alias Born 08/25/2006

steveporsche

Re: julescat post# 89118

Friday, 01/15/2010 5:19:15 PM

Friday, January 15, 2010 5:19:15 PM

Post# of 252235
Nope, you are double counting some of those shares:

January 15, 2010 4:27 PM EST

In a 13G filing after the close on Dendreon (Nasdaq: DNDN), Steven Cohen's S.A.C. Capital disclosed a 5.5%, or 7,282,030 share, stake in the biotech company. The firm held just 150,000 shares of DNDN at the quarter ended September 30, 2009. A 13G indicates a passive investment above 5%.



Dendreon is expected to be given approval for prostate cancer treatment Provenge which is expected to be blockbuster therapy for this indication and maybe others.

http://www.streetinsider.com/13Gs/Cohens+S.A.C.+Capital+Discloses+5.5%+Stake+In+Dendreon+(DNDN)/5252197.html


Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up